#Taiwan #Taipei #Cipla #Formosa #Clobetasol

Cipla and Formosa Pharmaceuticals Announce Licensing Agreement for Clobetasol Suspension

In a strategic move aimed at improving patient care in ophthalmology, Taiwan's Formosa Pharmaceuticals has entered into an exclusive licensing agreement with India's Cipla Limited. This partnership will focus on the commercialization of Clobetasol Propionate Ophthalmic Suspension, a product designed to provide effective treatment for post-operative inflammation and pain in patients undergoing ocular surgery. Under the terms of the agreement, Cipla is granted the exclusive rights to market this novel therapy in eleven countries, including India, Nepal, Sri Lanka, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, and Colombia.

The licensed product, which is identified as APP13007, represents a significant advancement in ophthalmic treatments. Clobetasol is a patented pharmaceutical that has gained approval from the USFDA. The formulation allows for a convenient dosing schedule of just two administrations per day over a two-week period, providing rapid and sustained relief without the need for tapering. This straightforward regimen is expected to greatly benefit postoperative patients facing discomfort from eye surgeries.

Erick Co, the President and CEO of Formosa Pharmaceuticals, expressed enthusiasm about this collaboration, emphasizing Cipla's esteemed recognition in the global pharmaceutical landscape. He highlighted the opportunity to leverage Cipla's existing network to expand patient access to innovative treatments for ocular surgery recovery.

On Cipla's side, Achin Gupta, the Global Chief Operating Officer, stated that the partnership marks a pivotal moment for the company, marking their first multi-regional licensing agreement specifically within the realm of ophthalmology. Gupta underscored Cipla’s commitment to introducing effective treatments for patients worldwide, indicating the potential impact of APP13007 on the market.

Cipla's ophthalmology segment is dedicated to developing therapies addressing various conditions, including glaucoma and dry eye disease, as well as ocular infections and retinal disorders. This alliance not only showcases their commitment to advancing eye care healthcare solutions but also reflects their broader objectives to enhance their pharmaceutical portfolio through innovative therapies.

The licensing agreement entails a structure of upfront payments, milestone royalties, and additional value drivers throughout the term of collaboration. This strategic initiative is anticipated to aid in expanding the availability of crucial ophthalmic solutions to diverse markets while enhancing patient welfare.

About Formosa Pharmaceuticals, Inc.
Formosa Pharmaceuticals is a biotechnology company currently focusing on ophthalmology and oncology. It specializes in proprietary nanoparticle formulation technology (APNT®), which is instrumental in enhancing the delivery and bioavailability of active pharmaceutical ingredients in various formulations. Their approach has shown success in administering significantly challenging drug agents, improving patient outcomes in treatment.

About Cipla
Founded in 1935, Cipla has grown to become a significant player in the global pharmaceutical industry, known for its sustainable growth strategies and expansive product portfolio that spans multiple therapeutic segments, including respiratory and anti-retroviral therapies. With over 46 manufacturing sites worldwide, Cipla is recognized for its commitment to providing accessible healthcare solutions, making a positive impact on patients' lives globally.

This new partnership between Cipla and Formosa showcases their commitment to advancing healthcare solutions and exemplifies the promising future of ophthalmic therapies.